Protocol Ledger

NCT06280716 · Phase III · COMPLETED

A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

Interventional Phase III clinical trial protocol NCT06280716 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-04-24 Enrollment: 301 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06280716
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)301 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06280716
Protocol FieldVerified Registry Value
NCT IdentifierNCT06280716
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment301 participants (ACTUAL)
Registered Start Date2024-04-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI